Shinpoong Pharmaceutical Co., Ltd.

As of June 30, 2026, Shinpoong Pharmaceutical Co., Ltd. carries a market capitalization of 435.38B, placing it among publicly traded companies globally. Its enterprise value stands at 418.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shinpoong Pharmaceutical Co., Ltd. has 51.71M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.89, and the price-to-book ratio stands at 1.58.

As of June 30, 2026, Shinpoong Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 29.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 155.41 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 418.31B versus a market cap of 435.38B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shinpoong Pharmaceutical Co., Ltd. maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.16, indicating elevated leverage, while an interest coverage ratio of 4.62 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shinpoong Pharmaceutical Co., Ltd. posted a negative return on equity (ROE) of -0.31, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) is negative at -116.49, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) is negative at -0.23, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -125.41, pointing to unprofitable operations over the period. The company generates approximately 298.09M in revenue per employee across its workforce of 802.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.25 indicates how many times Shinpoong Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shinpoong Pharmaceutical Co., Ltd. recorded 752.17M in income tax expense. That works out to an effective tax rate of 13,304.74, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.65M, leaving -815.28M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Shinpoong Pharmaceutical Co., Ltd.'s stock has declined approximately 32.89% over the past 52 weeks. The 50-day moving average sits at 9,413.20, while the 200-day moving average is 10,363.70.

Over the twelve months ended June 30, 2026, Shinpoong Pharmaceutical Co., Ltd. generated 239.07B in revenue and converted that into -815.28M in net income, yielding earnings per share of -13.88. EBITDA reached 14.01B, while operating income came in at 2.69B.

As of June 30, 2026, Shinpoong Pharmaceutical Co., Ltd. holds 72.31B in cash and equivalents against 53.28B in total debt, resulting in a net debt position of 4.31B. Total book value stands at 276.08B, with working capital of 137.88B providing operational flexibility.

Shinpoong Pharmaceutical Co., Ltd. produced 17.57B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.04B in capital expenditures, free cash flow totaled 13.53B - equivalent to 251.58 per share.

Over the twelve months ended June 30, 2026, Shinpoong Pharmaceutical Co., Ltd. posted a gross margin of 42.71, reflecting its pricing power and cost economics. The operating margin of 1.13 and net profit margin of -0.34 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.99, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.49, meaning Shinpoong Pharmaceutical Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shinpoong Pharmaceutical Co., Ltd.'s most recent stock split took place on December 29, 2014 with a 25:26 split ratio.

As of June 30, 2026, Shinpoong Pharmaceutical Co., Ltd. has an Altman Z-Score of 4.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.